Related Experiment Video

Updated: Aug 31, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment

Meng Cai1,2,3, Jie Zhu1, Guangxin Zhou1,2

  • 1Department of Orthopedics, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China.

Computational and Mathematical Methods in Medicine
|August 22, 2022
PubMed
Abstract

Insights

Anlotinib demonstrates efficacy in refractory bone and soft tissue sarcoma. Combination therapy with chemotherapy did not significantly improve outcomes compared to anlotinib alone, suggesting anlotinib is effective as a first-line treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Refractory bone and soft tissue sarcoma present significant treatment challenges.
  • Identifying effective therapeutic strategies is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of anlotinib in patients with refractory bone and soft tissue sarcoma.
  • To compare anlotinib monotherapy with anlotinib plus chemotherapy.

Main Methods:

  • Retrospective analysis of 47 patients with refractory bone and soft tissue sarcoma treated with anlotinib.
  • Evaluation of overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
  • Assessment of adverse reactions.

Main Results:

  • Among 13 osteosarcoma patients, 54% achieved stable disease (SD), with median PFS of 4.4 months and median OS of 15.7 months.
  • In 31 soft tissue sarcoma patients, ORR was 19%, DCR was 71%, median PFS was 5.4 months, and median OS was 17.9 months.
  • Anlotinib plus chemotherapy showed a higher ORR (38%) than monotherapy (6%), but this was not statistically significant in all analyses. Common grade 3/4 adverse events included pneumothorax and pleural effusion.

Conclusions:

  • Anlotinib monotherapy exhibits encouraging efficacy and favorable tolerability in refractory bone and soft tissue sarcoma.
  • Anlotinib plus chemotherapy did not demonstrate a significant clinical benefit over anlotinib alone.
  • Anlotinib may be more effective as a first-line treatment for refractory bone and soft tissue sarcoma.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K